Related Experiment Video
Updated: May 15, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet function monitoring and clopidogrel
Andrew R Harper1, Matthew J Price
1Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. a.r.harper@ncl.ac.uk
Insights
Antiplatelet therapy using P2Y12 inhibitors like clopidogrel is crucial after percutaneous coronary intervention. Measuring platelet function may personalize therapy, but more trial data is needed to support routine use.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is standard after percutaneous coronary intervention (PCI) and for acute coronary syndrome (ACS).
- Individual variability in the antiplatelet effect of clopidogrel exists, with high on-treatment platelet reactivity linked to increased cardiovascular events post-PCI, including stent thrombosis.
Purpose of the Study:
- To explore the potential of incorporating platelet function testing into clinical practice.
- To assess if personalized antiplatelet therapy following PCI can be achieved through platelet function monitoring.
Main Methods:
- Review of existing literature on antiplatelet therapy and platelet function testing.
- Analysis of the association between high on-treatment platelet reactivity and cardiovascular events post-PCI.
Main Results:
- High on-treatment platelet reactivity is a significant risk factor for adverse cardiovascular outcomes after PCI.
- Ex vivo methods for measuring P2Y12 antagonist effects are clinically available.
Conclusions:
- Platelet function testing offers a potential strategy for tailoring antiplatelet therapy post-PCI.
- Definitive randomized trials are required to establish the routine use of platelet function testing in guiding antiplatelet therapy after PCI.
Abstract:
Antiplatelet therapy with aspirin and a platelet P2Y12 receptor antagonist reduces thrombotic and ischemic events after percutaneous coronary intervention and acute coronary syndrome. The platelet inhibitory effect of the thienopyridine clopidogrel varies widely among individuals, and high on-treatment platelet reactivity has been associated with a substantial hazard for post-PCI cardiovascular events, including stent thrombosis. The clinical availability of ex vivo methods to measure the antiplatelet effect of P2Y12 antagonists raises the possibility that incorporating platelet function testing into clinical practice could facilitate a stratified and efficient approach to antiplatelet therapy following PCI, although data from definitive randomized trials supporting a routine approach are currently lacking.
More Related Videos
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...

